Abstract
Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have